• Online Features  This Article  • Full text  • PDF  • eTable  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (32)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Dementias  • Neurogenetics  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Barbara J. Snider, MD, PhD; Anne M. Fagan, PhD; Catherine Roe, PhD; Aarti R. Shah, MS; Elizabeth A. Grant, PhD; Chengjie Xiong, PhD; John C. Morris, MD; David M. Holtzman, MD

Arch Neurol. 2009;66(5):638-645.

Background  Cerebrospinal fluid (CSF) levels of Aβ peptide 1-42 (Aβ 42), tau, and phosphorylated tau (ptau) are potential biomarkers of Alzheimer disease.

Objective  To determine whether Aβ 42, tau, and ptau predict the rate of cognitive change in individuals with very mild dementia of the Alzheimer type (DAT).

Design  Retrospective analysis of CSF biomarkers and clinical data.

Setting  An academic Alzheimer disease research center.

Participants  Research volunteers in a longitudinal study of aging and cognition. Participants (n = 49) had a clinical diagnosis of very mild DAT with a Clinical Dementia Rating (CDR) of 0.5 at the time of lumbar puncture. All the participants had at least 1 follow-up assessment (mean [SD] follow-up, 3.5 [1.8] years).

Main Outcome Measures  Baseline CSF levels of Aβ 42, Aβ 40, tau, and ptau at threonine 181 (ptau181) and the rate of dementia progression as measured using the CDR sum of boxes (CDR-SB) score and psychometric performance.

Results  The rate of dementia progression was significantly more rapid in individuals with lower baseline CSF Aβ 42 levels, higher tau or ptau181 levels, or high tau: Aβ 42 ratios. For example, the annual change in the CDR-SB score was 1.1 for the lowest 2 tertiles of Aβ 42 values and 0.3 for the highest tertile of Aβ 42 values.

Conclusions  In individuals with very mild DAT, lower CSF Aβ 42 levels, high tau or ptau181 levels, or high tau:Aβ 42 ratios quantitatively predict more rapid progression of cognitive deficits and dementia. Biomarkers of CSF may be useful prognostically and to identify individuals who are more likely to progress for participation in therapeutic clinical trials.

Author Affiliations: Department of Neurology (Drs Snider, Fagan, Roe, Morris, and Holtzman and Ms Shah) and Division of Biostatistics (Drs Grant and Xiong), Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

The Challenge and Public Health Implications of Alzheimer Overdiagnosis in the Oldest Old—Reply
Nigel J. Cairns and John C. Morris
Arch Neurol. 2010;67(7):900-901.
EXTRACT | FULL TEXT  

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2009;66(5):552-553.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence for Ordering of Alzheimer Disease Biomarkers
Jack et al.
Arch Neurol 2011;68:1526-1535.
ABSTRACT | FULL TEXT  

Rapidly Progressive Alzheimer Disease
Schmidt et al.
Arch Neurol 2011;68:1124-1130.
ABSTRACT | FULL TEXT  

Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of {beta}-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology
Fagan et al.
Arch Neurol 2011;68:1137-1144.
ABSTRACT | FULL TEXT  

The BTB and CNC Homology 1 (BACH1) Target Genes Are Involved in the Oxidative Stress Response and in Control of the Cell Cycle
Warnatz et al.
J. Biol. Chem. 2011;286:23521-23532.
ABSTRACT | FULL TEXT  

Plasma {beta}-Amyloid Linked to Cognitive Decline
Growdon and Hyman
Arch Neurol 2011;68:799-801.
FULL TEXT  

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
Jack et al.
Brain 2010;133:3336-3348.
ABSTRACT | FULL TEXT  

Sharpen That Needle
Herskovits and Growdon
Arch Neurol 2010;67:918-920.
FULL TEXT  

The Challenge and Public Health Implications of Alzheimer Overdiagnosis in the Oldest Old--Reply
Cairns and Morris
Arch Neurol 2010;67:900-901.
FULL TEXT  

Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum: Normal Aging, Mild Cognitive Impairment, and Alzheimer Disease
Okonkwo et al.
Arch Neurol 2010;67:688-696.
ABSTRACT | FULL TEXT  

CSF biomarkers predict a more malignant outcome in Alzheimer disease
Wallin et al.
Neurology 2010;74:1531-1537.
ABSTRACT | FULL TEXT  

Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults
Stomrud et al.
Arch Neurol 2010;67:217-223.
ABSTRACT | FULL TEXT